Read the latest press releases for 4D pharma plc.

Click on a news title to read full details. For Regulatory News Service (RNS) announcements please click here.

Press release archive
Clinical
4D pharma plc commences Phase I/II asthma trial
8 Jul 2019, 09:00
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics,…
4D to present Phase Ib results of Thetanix in paediatric Crohn's disease at ESPGHAN meeting
6 Jun 2019, 10:36
4D pharma plc (AIM: DDDD) today announced that data from the completed Phase Ib clinical study of…
Presentations
4D presents MRx0518 combination study at ASCO 2019, Chicago, USA
3 Jun 2019, 09:00
4D pharma plc announces the presentation of a poster detailing its Phase I/II clinical study of…
4D featured in The Telegraph
24 May 2019, 12:00
Freeze-dried gut bacteria could be the key to tackling asthma, Alzheimer's, Parkinson's disease and…
4D to Present Phase Ib Clinical Data on Thetanix®
16 May 2019, 09:00
4D pharma plc (AIM: DDDD), a pharmaceutical company focusing on the development of Live…
4D announces participation in Neuro4D Conference, Frankfurt, Germany
13 May 2019, 08:00
4D’s Research and Development team is giving a poster presentation on preclinical data from the…
4D to present preclinical data on neurodegenerative disorders programme
2 May 2019, 09:00
4D pharma will present preclinical data on its neurodegenerative disorders programme targeting…
Clinical Update – MRx0518 oncology programmes
29 Apr 2019, 09:00
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics,…
Participation in Microbiome Conference
8 Mar 2019, 09:00
4D announces participation in Chardan’s Inaugural Microbiome Medicines Summit, USA
4D pharma publishes mechanistic data on MRx0518
29 Jan 2019, 09:00
4D pharma announces publication of data highlighting immuno-stimulatory properties of MRx0518
4D pharma Appoints Two Non-Executive Directors
8 Jan 2019, 09:00
4D pharma plc announces the appointment of Ed Baracchini, PhD, and Professor Axel Glasmacher, MD, as…
4D pharma and MD Anderson Cancer Center to Evaluate Live Biotherapeutics in Solid Tumours
7 Jan 2019, 09:00
4D pharma plc (AIM: DDDD) and The University of Texas MD Anderson Cancer Center today announced a…
Clinical Update - Blautix Phase II study
8 Nov 2018, 12:00
4D pharma plc announces first patient enrolment in Blautix IBS Phase II study
4D Announces Positive Data From Phase Ib Study of Thetanix in Paediatric Crohn's Disease Patients
24 Sep 2018, 12:00
4D pharma plc (AIM: DDDD), announces positive top-line results for its Phase Ib study of Thetanix in…
4D asthma publication
14 Aug 2018, 08:26
Data suggests that MRx0004 is a promising next-generation therapeutic for management of asthma

BACK TO TOP